In the last trading session, 10.01 million shares of the Allogene Therapeutics Inc (NASDAQ:ALLO) were traded, and its beta was 0.94. Most recently the company’s share price was $1.62, and it changed around -$0.01 or -0.61% from the last close, which brings the market valuation of the company to $351.97M. ALLO currently trades at a discount to its 52-week high of $4.63, offering almost -185.8% off that amount. The share price’s 52-week low was $1.32, which indicates that the current value has risen by an impressive 18.52% since then. We note from Allogene Therapeutics Inc’s average daily trading volume that its 10-day average is 4.07 million shares, with the 3-month average coming to 5.45 million.
Allogene Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.41. If we narrow it down even further, the data shows that 0 out of 18 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 5 recommended ALLO as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Allogene Therapeutics Inc is expected to report earnings per share of -0.28 for the current quarter.
Allogene Therapeutics Inc (NASDAQ:ALLO) trade information
Instantly ALLO has showed a red trend with a performance of -0.61% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.9500 on recent trading dayincreased the stock’s daily price by 16.92%. The company’s shares are currently down -23.94% year-to-date, but still down -16.49% over the last five days. On the other hand, Allogene Therapeutics Inc (NASDAQ:ALLO) is -28.16% down in the 30-day period. We can see from the shorts that 39.1 million shares have been sold at a short interest cover period of 4.24 day(s).
The consensus price target as assigned by Wall Street analysts is $33.5, which translates to bulls needing to increase their stock price by 95.16% from its current value. Analyst projections state that ALLO is forecast to be at a low of $7 and a high of $55.
Allogene Therapeutics Inc (ALLO) estimates and forecasts
The year-over-year growth rate is expected to be -41.55%, down from the previous year.
Consensus estimates provided by 13 financial analysts predict the company will bring in an average of 1.54k in revenue for the current quarter. 13 analysts expect Allogene Therapeutics Inc to make 1.54k in revenue for the current ending quarter. Analysts predict that the company’s current quarter sales will drop, forecast at -93.00%. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 6.26%. Allogene Therapeutics Inc earnings are expected to increase by 9.90% in 2025, but the outlook is negative -1.15% per year for the next five years.
ALLO Dividends
Allogene Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Mar-12.
Allogene Therapeutics Inc (NASDAQ:ALLO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 17.73% of Allogene Therapeutics Inc shares, and 77.84% of them are in the hands of institutional investors. The stock currently has a share float of 94.61%. Allogene Therapeutics Inc stock is held by 237.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 16.4491% of the shares, which is about 31.26 million shares worth $72.83 million.
TPG GP A, LLC, with 9.8493% or 18.72 million shares worth $43.61 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
SMALLCAP WORLD FUND INC and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 6.9 shares worth $11.17 million, making up 3.17% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 4.28 shares worth around $6.93 million, which represents about 1.97% of the total shares outstanding.
